First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial

P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, AS Mansfield, S Popat, T Jahan, S Antonia, Y Oulkhouir, Y Bautista, Robin Cornelissen, L Greillier, F Grossi, D Kowalski, J Rodríguez-Cid, P Aanur, A Oukessou, C BaudeletG Zalcman

Research output: Contribution to journalArticleAcademic

216 Citations (Scopus)

Fingerprint

Dive into the research topics of 'First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences